OMNI 360 Wealth Inc. Purchases 1,899 Shares of Johnson & Johnson (NYSE:JNJ)

OMNI 360 Wealth Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 57.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,221 shares of the company's stock after buying an additional 1,899 shares during the quarter. OMNI 360 Wealth Inc.'s holdings in Johnson & Johnson were worth $866,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Brighton Jones LLC increased its position in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC boosted its holdings in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after buying an additional 1,022 shares during the period. Proficio Capital Partners LLC boosted its holdings in shares of Johnson & Johnson by 22.0% in the fourth quarter. Proficio Capital Partners LLC now owns 19,951 shares of the company's stock worth $2,885,000 after buying an additional 3,594 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Johnson & Johnson in the fourth quarter worth about $1,339,878,000. Finally, Natural Investments LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $986,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on JNJ. Raymond James Financial lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a report on Thursday. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, June 21st. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $1.44 during mid-day trading on Thursday, hitting $157.72. The company's stock had a trading volume of 6,719,599 shares, compared to its average volume of 8,053,055. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. The firm has a market capitalization of $379.48 billion, a PE ratio of 17.54, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The stock's 50-day moving average is $153.67 and its two-hundred day moving average is $154.27.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion during the quarter, compared to analysts' expectations of $21.65 billion. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.30%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is 57.84%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.